 | | Hepatologists' Overview of Hepatic Steatosis |
|  | | Hepatologists' Overview of Hepatic Steatosis |
|
 | | Structure |
|  | | Laparoscopic view of a fatty liver |
|
 | | Definitions |
|  | | NAFLD—History |
|
 | | Spectrum of NAFLD |
|  | | NASH |
|
 | | Conditions Associated with NAFLD |
|  | | NASH—Risk Factors |
|
 | | Metabolic syndrome |
|  | | Obesity prevalence in Netherlands |
|
 | | NAFLD prevalence |
|  | | Pathogenesis of NASH |
|
 | | Pathogenesis of NASH (1) - Induction of insulin resistance |
|  | | Pathogenesis of NASH (2) - Induction of inflammation |
|
 | | Pathogenesis: “2 Hit” Paradigm |
|  | | Diagnostic strategy |
|
 | | NAFLD—Laboratory Findings |
|  | | Liver biopsy in NASH |
|
 | | Pathology NAFLD vs NASH |
|  | | Pathology NAFLD vs NASH |
|
 | | NAFLD—Imaging |
|  | | Steatosis on ultrasound |
|
 | | Natural History of NAFLD |
|  | | Impact of NAFLD on survival |
|
 | | Independent predictors of fibrosis progression |
|  | | Therapeutic options in NAFLD |
|
 | | Weight loss & Exercise |
|  | | Bariatric Surgery |
|
 | | Surgery for NASH |
|  | | Bariatric surgery improves hepatic steatosis |
|
 | | Bariatric surgery improves hepatic fibrosis |
|  | | Bariatric surgery improves steatohepatitis |
|
 | | Bariatric surgery for non-alcoholic steatohepatitis in obese patients. |
|  | | Liver Transplantation |
|
 | | Liver Transplantation |
|  | | Pathogenesis of NASH with Potential Sites for Therapy |
|
 | | Medical treatment for NASH |
|  | | Antihyperlipidemics |
|
 | | Statins |
|  | | Metformin |
|
 | | Metformin in non-diabetic NASH |
|  | | Thiazolidinediones |
|
 | | Insulin senzitizers in NASH |
|  | | Ursodeoxycholic acid |
|
 | | Antioxidants:Vitamin E |
|  | | PIVENS Trial |
|
 | | PIVENS |
|  | | Therapy for NASH |
|
 | | Conclusion |
|  | | Treatment “algoritm” |
|
 | | Management |
|  | | Conclusion |
|
 | | Despite a number of RCT’s no drug has shown to improve all important outcome measures No drug can be recommended at this stage |
|  | | Treatment of NASH Cirrhosis 3. Insulin Resistance Treatment |
|
 | | Fibrates |
|  | | Metformin in non-diabetic NASH |
|
 | | Orlistat |
|  | | Metformin Trials |
|
 | | Treatment of NASH Cirrhosis 4. Liver-specific therapies |
|  | | Slide 62 |
|
 | | Background |
|  | | 6-Ethyl Chenodeoxycholic Acid - INT-747 Semi-Synthetic Derivative of CDCA |
|
 | | Hypothesis |
|  | | Eligibility criteria |
|
 | | Type 2 Diabetes + NAFLD Exploratory Study |
|  | | Enrichment of INT-747 of serum Bile Acids- day 43 |
|
 | | % Δ Weight – All Patients |
|  | | Change in ELF Test Score – Day 0 to 43 |
|
 | | Aminotransferases |
|  | | Slide 72 |
|
 | | Slide 73 |
|  | | Slide 74 |
|
 | | Laparoscopic view of a fatty liver |
|  | | NAFLD-NASH Prevalence |
|
 | | Slide 77 |
|
Deel deze pagina met collega's en vrienden: